FDA Approves Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of Neuroblastoma

    NEXT STORY
    Molecular Diagnostics Market to Record over 7% Growth Rate and Hit USD 13873.6 Million by 2025; Advancements in this Field to Increase Productivity Level, states Fortune Business Insights™
    PREV STORY
    CB2 Insights Announces Results of Special Shareholders Meeting and Schedule for Q3 2020 Earnings Call
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Biopsy Devices Market Viewed As A Stepping Stone Towards A World Of Minimally Invasive Healthcare Diagnosis – MarketIntelReports

    Wilmington, Delaware, United States, March 26, 2017 (GLOBE NEWSWIRE) -- The report “World Biopsy ...

    author_avatar
    NASDAQ Market News

    Y-mAbs Announces Data to be Presented at 2020 ASCO Annual Meeting

    author_avatar
    NASDAQ Market News

    Basilea reports the launch of antifungal Cresemba® (isavuconazole) in Taiwan, triggering the second milestone payment related to Asia-Pacific

    author_avatar
    NASDAQ Market News